Matsuda Masaru sold $250K of ARQT

Matsuda Masaru (See Remarks) sold 9,989 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $25.03 ($0.25M total) on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Matsuda Masaru
Published Sep 10, 2026, 11:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 12:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
high confidence
Mentioned
$ARQT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

Provides transparency; investors may monitor future insider activity.

02

Market read

Routine insider sale with minimal market impact.

03

What to watch

Potential upcoming clinical data could offset sale impact.

Relevance 3/10Novelty 3/10Timing: post‑market filing on Sep 10, 2026

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$ARQTNeutralHigh confidence
Context

Officer Matsuda Masaru sold 9,989 ARQT shares for $249,986 via a 10b5-1 plan.

Expected impact

No material move expected.

Evidence & confidence

Sale size (~$250k) is small relative to market cap; insider is using pre‑arranged plan.

Market effects

None; biotech sector unchanged.

None; US market only.

Low

Counterpoint

Insider sale could signal concerns, but size is trivial.

Key entities

  • Arcutis Biotherapeutics, Inc.

    Biotech firm developing dermatology therapies.

  • Matsuda Masaru

    Company officer executing a 10b5-1 sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.